These analyses also demonstrated increased MTBP expression was associated with poor patient outcomes in glioblastomas (p = 7.344 × 10−5), gliomas (p = 4.4342 × 10−12 and 3.053 × 10−5), and renal cancer (p = 1.062 × 10−5). The gene discussed is MTBP; the disease is central nervous system cancer.